Q&A with Margaret Molloy, Global CMO, Siegel+Gale

MEDIA 7 | May 20, 2019

Margaret Molloy, Global CMO of Siegel+Gale has a 20-year track record as a business-to-business growth instigator, achieved by uniting brand building with demand generation. In Siegel+Gale’s Simplifiers series, Margaret Molloy interviews business leaders who put simplicity to work.

Considered a "CMO whisperer," Margaret is a highly influential CMO and convener of panels and roundtables. She has been recognized by Forbes as one of the top 10 CMOs on Twitter. Margaret also serves as the New York Chair of the Marketing Society

MEDIA 7: If we were to say to a bunch of people who know you, ‘Give us three adjectives that best describe you’, what would we hear?
MARGARET MOLLOY: 
Passionate, energetic and influential.

M7: What is your favourite part of working at Siegel+Gale?
MM:
Both our ethos—helping brands realize the power of simplicity, and the strategists, designers, researchers, and writers who deliver on that ethos to our clients. Our teams are truly simplifiers. I believe that in our harried, cluttered world, brands that focus on simplicity, win.


"It's incumbent on brands to be relevant in order to be part of a conversation that drives their business forward. And to be relevant, you must be in tune with your customers’ needs."

M7: What is the ‘power of simplicity’ that you’re helping CMOs and brand leaders realize?
MM: Simplicity is the ultimate driver of brand loyalty. It inspires people to spend more with a brand, motivates employees to deliver on a brand’s promise and ultimately, drives financial gain for those companies that embrace it.

M7: At Siegel+Gale, how do you align sales and marketing to achieve your branding goals?
MM:
There has always been a natural tension. A CMO’s job is to reconcile that tension by setting a vision for the brand and determining the resource allocation between short-term revenue targets and long-term brand value. At Siegel+Gale, we do not engage in random acts of marketing—all marketing is in the service of the brand and the revenue targets.


"A CMO’s job is to reconcile tension between brand-building programs and performance marketing by setting a vision for the brand and determining the resource allocation between short-term revenue targets and long-term brand value."

M7: Margaret, you were listed on Forbes Top 10 Most Influential Chief Marketing Officers on Social Media in 2017 and have won IrishCentral’s 2018 Creativity and Arts Award in Fashion and Design. How is social media transforming the marketing landscape and how do you see it evolving in future?
MM:
In previous eras, a brand’s responsibility was to broadcast its message and product offerings to the community. Today, with the advent of social media, it has become a multi-party dialogue. The fundamental shift is from controlling the brand message to engaging constituencies (i.e., customers, shareholders, the community at large). Therefore, it's incumbent on brands to be relevant in order to be part of a conversation that drives their business forward. And to be relevant, you must be in tune with your customers’ needs.  Social media is a great mechanism not only for engagement but also for listening.


"Simplicity is the ultimate driver of brand loyalty. It inspires people to spend more with a brand, motivates employees to deliver on a brand’s promise and ultimately, drives financial gain for those companies that embrace it."

M7: For your platform #WearingIrish, which channels helped you the most in reaching out to the target audience?
MM: I created WearingIrish to expose Ireland’s talented fashion designers to new markets and to showcase Irish fashion design on the global stage. Instagram is an obvious choice to reach shoppers and influencers; it’s a robust platform for any fashion brand because it's inherently visual.

In addition to Instagram, I leveraged my professional network on LinkedIn to build a broad-based board of advisors and potential collaborators for WearingIrish.

M7: What motivates you to get out of the bed in the morning?
MM:
I’m a connector, and I get my energy from convening the marketing community via live events and other programs. On a daily basis, I host conversations with ambitious CMOs and brand leaders about their challenges. I relish the opportunity to connect marketing leaders with the team at Siegel+Gale because of our depth of expertise in helping our clients build brands.

ABOUT SIEGEL+GALE

Siegel+Gale is the simplicity company. We seek it, defend it and embrace it in everything we do to help brands reach their true potential. Simplicity is the centerpiece of the strategies we develop that reveal the unique truths of an organization, the engaging stories we create that connect brands with their audiences and the meaningful experiences we deliver that are both unexpectedly fresh and remarkably clear.

Since 1969, Siegel+Gale has championed simplicity for leading corporations, nonprofits and government organizations worldwide. We have offices in New York, Los Angeles, San Francisco, London, Dubai, and Shanghai, but we’re willing to fly just about anywhere. We’re also not alone. As part of Brand Consulting Group, a division of Omnicom Group Inc., we have strong partners all around the world.

More C-Suite on deck

Q&A with Matthew Sappern, CEO at PeriGen

Media 7 | September 30, 2021

Matthew Sappern, CEO at PeriGen, had served as a corporate officer for Eclipsys Corporation before and during its merger with Allscripts. Leading up to the merger, Sappern served as Eclipsys Senior Vice President of Professional Services, responsible for the company’s $100M consulting, implementation and training P&L. Sappern joined Eclipsys in January 2003, as VP of product development in the software engineering division. Over a time of three years, he came to run 75 percent of the development operation and oversaw the delivery of three critical enterprise software releases in record time for the company.

Read More

Q&A with Anna Baecklund, CTO & Founder at Oppioo

Media 7 | September 21, 2021

Anna Baecklund, CTO & Founder at Oppioo, is a Data Scientist Leader, A skilled communicator capable of explaining complex issues with clarity to diverse audiences. With MSc in engineering physics, Anna is responsible for leading innovation using data science including the development of new insights, advanced modelling techniques, and AI capabilities. With Oppio, An AI companion app, she aims to motivate cancer patients who want to speed up and improve their rehab.

Read More

Q&A with Bill Gianoukos, CEO at Goodpath

Media 7 | September 14, 2021

Bill Gianoukos, Co-founder and CEO of Goodpath, started Goodpath in 2018 with a mission to improve the ‘Quality Of Life’ for those suffering from chronic conditions. He is also a Mentor at Techstars, and an Investor at Wappier: Intelligent Revenue Management.

Read More

Q&A with Matthew Sappern, CEO at PeriGen

Media 7 | September 30, 2021

Matthew Sappern, CEO at PeriGen, had served as a corporate officer for Eclipsys Corporation before and during its merger with Allscripts. Leading up to the merger, Sappern served as Eclipsys Senior Vice President of Professional Services, responsible for the company’s $100M consulting, implementation and training P&L. Sappern joined Eclipsys in January 2003, as VP of product development in the software engineering division. Over a time of three years, he came to run 75 percent of the development operation and oversaw the delivery of three critical enterprise software releases in record time for the company.

Read More

Q&A with Anna Baecklund, CTO & Founder at Oppioo

Media 7 | September 21, 2021

Anna Baecklund, CTO & Founder at Oppioo, is a Data Scientist Leader, A skilled communicator capable of explaining complex issues with clarity to diverse audiences. With MSc in engineering physics, Anna is responsible for leading innovation using data science including the development of new insights, advanced modelling techniques, and AI capabilities. With Oppio, An AI companion app, she aims to motivate cancer patients who want to speed up and improve their rehab.

Read More

Q&A with Bill Gianoukos, CEO at Goodpath

Media 7 | September 14, 2021

Bill Gianoukos, Co-founder and CEO of Goodpath, started Goodpath in 2018 with a mission to improve the ‘Quality Of Life’ for those suffering from chronic conditions. He is also a Mentor at Techstars, and an Investor at Wappier: Intelligent Revenue Management.

Read More

Related News

HEALTH TECHNOLOGY

Veranex Expands European MedTech Capabilities With Acquisition of Medidee

Veranex and Medidee Services | September 21, 2022

Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry, announced that it has acquired Medidee, a top MedTech consultancy company headquartered in Lausanne, Switzerland. As a trusted European regulatory and quality service consultancy joining Veranex, Medidee expands and strengthens regulatory affairs, clinical development, and quality assurance services and capabilities for MedTech companies across Europe and the world. This improved ability to navigate the European Union’s Medical Device and In Vitro Diagnostic Device Regulations challenges supports truly full-service MedTech product development and commercialization. “Our acquisition of Medidee significantly expands our European footprint while also materially expanding the scale and scope of the clinical studies we can manage. The combined organization offers offices and expertise across Europe, the U.S., and Asia, augmenting our ability to help MedTech innovators achieve FDA and CE Mark approvals and uninterrupted market access for new as well as proven medical technologies that advance patient care.” Veranex CEO David Dockhorn With Medidee’s 11 locations across Europe, India, and Asia-Pacific, and Veranex’s 13 locations across the U.S., Europe, and China, the company now has unprecedented reach to serve clients with a full spectrum of integrated concept-to-commercialization services — design, engineering, regulatory, quality, preclinical research, clinical development, clinical operations, commercial strategy, and market access services — all under one umbrella. Medidee is one of the Top 3 medical device consultancy service providers in Europe uniquely positioned as a leader in future key areas such as digital health, machine learning, and cybersecurity. The company also brings expertise in clinical research exclusively focused on medical devices and in vitro diagnostics. “Medidee has a proven track record serving regulatory, clinical, and quality needs for companies of all sizes, with consulting expertise and clinical trial support in increasingly diverse therapeutic areas and technology categories across multiple geographies,” shared Medidee co-founders Kim Rochat, Philippe Etter, and Michael Maier. “With these services, coupled with the global infrastructure of Veranex, we expand expertise and resources for the benefit of our clients as well as for all EU innovative manufacturers wishing to access rapidly and efficiently the U.S. market and beyond. We look forward to providing these additional strengths and capabilities,” added the co-founders who take on new roles in the combined organization. About Veranex Veranex is the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry. Offering expert guidance from concept to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its comprehensive solutions unify and streamline the entire development process. Veranex is backed by Summit Partners, Accelmed, and Lauxera Capital Partners. About Medidee Services With sites in Switzerland, Germany, Denmark, Belgium, Spain, USA, and APAC, Medidee is a global services supplier serving companies ranging from academic startups to majors. Medidee was established by three partners, all experts in the field of medical devices. With 50 experts in all fields necessary to ensure compliance with the most stringent requirements, Medidee provides the necessary competencies to ensure and demonstrate compliance with all key medical device regulations. Medidee expends regularly to provide the best resources and competencies and supports more than 350 manufactures all over the world.

Read More

HEALTH TECHNOLOGY

Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA

Antengene Corporation Limited | September 19, 2022

Antengene Corporation Limited a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, announced that ATG-101, the company's in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. This ODD will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development and the future registration of ATG-101. At present, no PD-L1/4-1BB bispecific antibody has been approved for the treatment of pancreatic cancer worldwide. Orphan Drugs, also known as Rare Disease Drugs, refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases or conditions. Orphan Drug Designations by the U.S. FDA are meant to support the development of drug candidates that could potentially bring substantial therapeutic benefits to patients with rare diseases and to provide incentives to the subsequent development, registration and commercialization to designated drugs. Those incentives include tax credit on expenditures incurred in clinical studies, a waiver of the New Drug Application (NDA) fee, and 7-year market exclusivity in the U.S. regardless of the patent status of the designated drug. Pancreatic cancer is a highly malignant type of gastrointestinal cancer. According to the statistics by the World Health Organization (WHO), pancreatic cancer was ranked 13th and 7th globally by its incidence and mortality rates in 2012. In 2018, the U.S. reported over 55,000 newly- diagnosed pancreatic cancer cases and 44,330 related deaths. Whereas still defined as an orphan disease currently, it is projected that by 2030, pancreatic cancer will become the second most common cause of cancer-related deaths. ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. In preclinical studies, ATG-101 demonstrated significant anti-tumor activity in animal models of resistant tumors as well as those that had progressed on anti-PD-1/L1 treatment. Furthermore, ATG-101 has also shown an excellent safety profile in Good Laboratory Practice (GLP) toxicology studies. ATG-101 is the first PD-L1/4-1BB bispecific antibody entering clinical development in Australia and is currently being evaluated in clinical studies in Australia, China, and the U.S. "We are very encouraged by this Orphan Drug Designation from the U.S. FDA and are hopeful that ATG-101 will offer a novel therapeutic to patients with pancreatic cancer. As Antengene's first in-house developed asset with global rights, ATG-101 has already entered clinical development in Australia, China, and the U.S. We will strive to accelerate the global clinical development of ATG-101 in efforts to provide a new treatment option to patients around the world." Dr. Bo Shan, Antengene's Chief Scientific Officer About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a broad and expanding pipeline of 15 clinical and preclinical assets, of which 10 are global rights assets, and 5 came with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 24 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® already approved in mainland China, South Korea, Singapore and Australia.

Read More

HEALTH TECHNOLOGY

Zynx Health Introduces Complimentary Monkeypox Order Set and Care Plan Bundle

Zynx Health | September 20, 2022

Zynx Health announced that it has published new order set and care plan guidelines to aid clinicians in the treatment of patients diagnosed with monkeypox. Created by the Zynx Clinical Team and based on recommendations from World Health Organization and the Centers for Disease Control and Prevention, the content is available as a single, downloadable PDF on the Zynx Health website. Given the public health emergency, this content is being made available at no cost. “As monkeypox cases continue to rise, and with hospitals still facing shortfalls in the wake of the COVID-19 pandemic, our Zynx clinicians have developed and deployed this comprehensive order set and care plan bundle to alleviate the burden of researching the underlying evidence and then building the associated clinical decision support from scratch,” said Chuck Tuchinda, MD, president of Zynx Health. “The monkeypox content on the Zynx site is comprehensive, evidence-based, and ready for use.” The Zynx Clinical Team will continue to update its monkeypox care guidance as new evidence emerges and best-practice recommendations evolve. About Zynx Health Zynx Health, a market leader in providing evidence- and experience-based clinical improvement solutions since 1996 and part of the Hearst Health network, provides healthcare professionals with vital information and processes that guide care decisions and reduce complexity across the entire patient journey in a way that leads to healthier lives for all. Named the “Best in KLAS” Category Leader for Clinical Decision Support – Care Plans and Order Sets in 2021 and 2022, Zynx is a pioneer and market leader in evidence- and experience-based clinical solutions that help health systems improve patient outcomes, financial outcomes, clinical engagement, and technology performance. With Zynx Health, healthcare organizations exceed industry demands for delivering high-quality care at lower costs under value-based reimbursement models. About Hearst Health The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Each year in the U.S., care guidance from Hearst Health reaches 85% of discharged patients, 205 million insured individuals, 103 million home health visits, and 3.2 billion dispensed prescriptions. The Hearst Health network includes FDB Zynx Health, MCG, Homecare Homebase, and MHK. Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen.

Read More

HEALTH TECHNOLOGY

Veranex Expands European MedTech Capabilities With Acquisition of Medidee

Veranex and Medidee Services | September 21, 2022

Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry, announced that it has acquired Medidee, a top MedTech consultancy company headquartered in Lausanne, Switzerland. As a trusted European regulatory and quality service consultancy joining Veranex, Medidee expands and strengthens regulatory affairs, clinical development, and quality assurance services and capabilities for MedTech companies across Europe and the world. This improved ability to navigate the European Union’s Medical Device and In Vitro Diagnostic Device Regulations challenges supports truly full-service MedTech product development and commercialization. “Our acquisition of Medidee significantly expands our European footprint while also materially expanding the scale and scope of the clinical studies we can manage. The combined organization offers offices and expertise across Europe, the U.S., and Asia, augmenting our ability to help MedTech innovators achieve FDA and CE Mark approvals and uninterrupted market access for new as well as proven medical technologies that advance patient care.” Veranex CEO David Dockhorn With Medidee’s 11 locations across Europe, India, and Asia-Pacific, and Veranex’s 13 locations across the U.S., Europe, and China, the company now has unprecedented reach to serve clients with a full spectrum of integrated concept-to-commercialization services — design, engineering, regulatory, quality, preclinical research, clinical development, clinical operations, commercial strategy, and market access services — all under one umbrella. Medidee is one of the Top 3 medical device consultancy service providers in Europe uniquely positioned as a leader in future key areas such as digital health, machine learning, and cybersecurity. The company also brings expertise in clinical research exclusively focused on medical devices and in vitro diagnostics. “Medidee has a proven track record serving regulatory, clinical, and quality needs for companies of all sizes, with consulting expertise and clinical trial support in increasingly diverse therapeutic areas and technology categories across multiple geographies,” shared Medidee co-founders Kim Rochat, Philippe Etter, and Michael Maier. “With these services, coupled with the global infrastructure of Veranex, we expand expertise and resources for the benefit of our clients as well as for all EU innovative manufacturers wishing to access rapidly and efficiently the U.S. market and beyond. We look forward to providing these additional strengths and capabilities,” added the co-founders who take on new roles in the combined organization. About Veranex Veranex is the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry. Offering expert guidance from concept to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its comprehensive solutions unify and streamline the entire development process. Veranex is backed by Summit Partners, Accelmed, and Lauxera Capital Partners. About Medidee Services With sites in Switzerland, Germany, Denmark, Belgium, Spain, USA, and APAC, Medidee is a global services supplier serving companies ranging from academic startups to majors. Medidee was established by three partners, all experts in the field of medical devices. With 50 experts in all fields necessary to ensure compliance with the most stringent requirements, Medidee provides the necessary competencies to ensure and demonstrate compliance with all key medical device regulations. Medidee expends regularly to provide the best resources and competencies and supports more than 350 manufactures all over the world.

Read More

HEALTH TECHNOLOGY

Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA

Antengene Corporation Limited | September 19, 2022

Antengene Corporation Limited a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, announced that ATG-101, the company's in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. This ODD will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development and the future registration of ATG-101. At present, no PD-L1/4-1BB bispecific antibody has been approved for the treatment of pancreatic cancer worldwide. Orphan Drugs, also known as Rare Disease Drugs, refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases or conditions. Orphan Drug Designations by the U.S. FDA are meant to support the development of drug candidates that could potentially bring substantial therapeutic benefits to patients with rare diseases and to provide incentives to the subsequent development, registration and commercialization to designated drugs. Those incentives include tax credit on expenditures incurred in clinical studies, a waiver of the New Drug Application (NDA) fee, and 7-year market exclusivity in the U.S. regardless of the patent status of the designated drug. Pancreatic cancer is a highly malignant type of gastrointestinal cancer. According to the statistics by the World Health Organization (WHO), pancreatic cancer was ranked 13th and 7th globally by its incidence and mortality rates in 2012. In 2018, the U.S. reported over 55,000 newly- diagnosed pancreatic cancer cases and 44,330 related deaths. Whereas still defined as an orphan disease currently, it is projected that by 2030, pancreatic cancer will become the second most common cause of cancer-related deaths. ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile. In preclinical studies, ATG-101 demonstrated significant anti-tumor activity in animal models of resistant tumors as well as those that had progressed on anti-PD-1/L1 treatment. Furthermore, ATG-101 has also shown an excellent safety profile in Good Laboratory Practice (GLP) toxicology studies. ATG-101 is the first PD-L1/4-1BB bispecific antibody entering clinical development in Australia and is currently being evaluated in clinical studies in Australia, China, and the U.S. "We are very encouraged by this Orphan Drug Designation from the U.S. FDA and are hopeful that ATG-101 will offer a novel therapeutic to patients with pancreatic cancer. As Antengene's first in-house developed asset with global rights, ATG-101 has already entered clinical development in Australia, China, and the U.S. We will strive to accelerate the global clinical development of ATG-101 in efforts to provide a new treatment option to patients around the world." Dr. Bo Shan, Antengene's Chief Scientific Officer About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a broad and expanding pipeline of 15 clinical and preclinical assets, of which 10 are global rights assets, and 5 came with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 24 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® already approved in mainland China, South Korea, Singapore and Australia.

Read More

HEALTH TECHNOLOGY

Zynx Health Introduces Complimentary Monkeypox Order Set and Care Plan Bundle

Zynx Health | September 20, 2022

Zynx Health announced that it has published new order set and care plan guidelines to aid clinicians in the treatment of patients diagnosed with monkeypox. Created by the Zynx Clinical Team and based on recommendations from World Health Organization and the Centers for Disease Control and Prevention, the content is available as a single, downloadable PDF on the Zynx Health website. Given the public health emergency, this content is being made available at no cost. “As monkeypox cases continue to rise, and with hospitals still facing shortfalls in the wake of the COVID-19 pandemic, our Zynx clinicians have developed and deployed this comprehensive order set and care plan bundle to alleviate the burden of researching the underlying evidence and then building the associated clinical decision support from scratch,” said Chuck Tuchinda, MD, president of Zynx Health. “The monkeypox content on the Zynx site is comprehensive, evidence-based, and ready for use.” The Zynx Clinical Team will continue to update its monkeypox care guidance as new evidence emerges and best-practice recommendations evolve. About Zynx Health Zynx Health, a market leader in providing evidence- and experience-based clinical improvement solutions since 1996 and part of the Hearst Health network, provides healthcare professionals with vital information and processes that guide care decisions and reduce complexity across the entire patient journey in a way that leads to healthier lives for all. Named the “Best in KLAS” Category Leader for Clinical Decision Support – Care Plans and Order Sets in 2021 and 2022, Zynx is a pioneer and market leader in evidence- and experience-based clinical solutions that help health systems improve patient outcomes, financial outcomes, clinical engagement, and technology performance. With Zynx Health, healthcare organizations exceed industry demands for delivering high-quality care at lower costs under value-based reimbursement models. About Hearst Health The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Each year in the U.S., care guidance from Hearst Health reaches 85% of discharged patients, 205 million insured individuals, 103 million home health visits, and 3.2 billion dispensed prescriptions. The Hearst Health network includes FDB Zynx Health, MCG, Homecare Homebase, and MHK. Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen.

Read More